Haemonetics price target lowered to $90 from $95 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics to $90 from $95 and keeps a Neutral rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant."